ARTiFACTS
ARTiFACTS operates Artifacts VERIFY, a SaaS platform combining PAD field testing, AI-powered mobile diagnostics, blockchain-secured LIMS, and certified laboratory confirmation to detect substandard and falsified pharmaceuticals for academic researchers, LMIC healthcare providers, and pharmaceutical supply chain stakeholders across nine-plus countries.
- Company typePrivate
- Founded2018
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What ARTiFACTS does
ARTiFACTS (Artifactsofresearch, Inc.) is a US-based SaaS company that operates the Artifacts VERIFY platform for detecting substandard and falsified prescription pharmaceuticals in the global drug supply chain. The platform combines low-cost Paper Analytical Device (PAD) field testing, a trained neural network that interprets PAD color results via a mobile application (PADReader), blockchain-distributed ledger storage for immutable chain-of-custody records, and certified laboratory confirmation (HPLC, LCMS) for suspect samples. It serves academic research institutions, healthcare providers in low- and middle-income countries, pharmaceutical supply chain stakeholders, and government regulators, with active deployments in Kenya, Uganda, Tanzania, Malawi, Cameroon, Ethiopia, India, Nepal, and the United States.
The company's commercial offering is an enterprise subscription that bundles the Verify LIMS, PAD consumables, the PADReader mobile app, laboratory processing services, training materials, and ongoing support, with quote-based pricing customized to the number of APIs monitored, sites, and geographies. Revenue is generated primarily through direct enterprise sales to research networks (notably the 29-institution DPAL network anchored by the Lieberman Lab at University of Notre Dame) and grant-funded deployments in sub-Saharan Africa. Funding has been non-dilutive to date, consisting of an NSF America's Seed Fund grant in 2021 and a five-year NIH grant in 2024 supporting chemotherapy drug surveillance.
In June 2026, Artifactsofresearch, Inc. donated 100% of its shares to the BoKoMo Foundation, a 501(c)(3) non-profit founded by Dr. Marya Lieberman, and now operates as a foundation subsidiary licensing its technology royalty-free. The company employs 1-10 staff and is led by Co-Founder and CEO Dave Kochalko (also co-founder of ORCID), with board oversight from Mike Boswood (former CEO of Truven Health Analytics) and George Moore (CTIO at CareMetx).
ARTiFACTS firmographics
Firmographics- Name
- ARTiFACTS
- Legal name
- Artifactsofresearch, Inc.
- Website
- https://artifacts.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ARTiFACTS operates Artifacts VERIFY, a SaaS platform combining PAD field testing, AI-powered mobile diagnostics, blockchain-secured LIMS, and certified laboratory confirmation to detect substandard and falsified pharmaceuticals for academic researchers, LMIC healthcare providers, and pharmaceutical supply chain stakeholders across nine-plus countries.
- Ownership category
- akta.pro rank
ARTiFACTS industry classification
Industry- Product category
- Pharmaceutical Quality Monitoring Software
- NAICS
- Testing Laboratories and Services (54138), Analytical Laboratory Instrument Manufacturing (334516), Other Measuring and Controlling Device Manufacturing (334519)
- SIC
- Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Forensic & Anti-Counterfeit Testing (Product Integrity) (HLAGADAM)
- akta.pro secondary industry
- Test & Measurement Equipment (Oscilloscopes, DAQ, signal analyzers, calibration benches) (IMAGAFAC)
Keywords
Where ARTiFACTS is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ARTiFACTS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Subscription (VERIFY Platform): Subscription-based SaaS model that includes access to the Verify LIMS database platform, PAD test cards, mobile PADReader App, laboratory processing services, training materials, and product support. Subscription tiers are quote-based and customized to organization size and monitoring requirements.
- Laboratory Services: HPLC, LCMS, and other sophisticated analyses are conducted by certified commercial laboratories to confirm APIs in suspect samples. These services are included as part of the subscription offering.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Standard Subscription |
| Subscription | Annual | Academic/Research License |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
ARTiFACTS product offering
Product offeringCore offering
ARTiFACTS operates a cloud-based SaaS platform called Artifacts VERIFY that combines paper analytical device (PAD) field testing of medicines, AI-powered mobile diagnostics, certified laboratory confirmation (HPLC/LCMS), and blockchain-secured data analytics to detect and report substandard and falsified pharmaceuticals across the supply chain. The platform provides a Laboratory Information Management System (LIMS) for tracking samples, protocols, results, users, and procedures, and delivers real-time reporting by API, location, lot number, and manufacturer.
Differentiator
Problem solved
Functional benefit
Brands
- ARTiFACTS File: Original platform for researchers for curation of ancillary scientific research material (grey literature) enabling proof-of-existence and data management.
- Artifacts VERIFY
Products and services
- Artifacts VERIFY Comprehensive post-market surveillance SaaS system for identifying and reporting substandard and falsified drugs in the pharmaceutical supply chain. Combines PAD testing, AI-powered mobile diagnostics, laboratory confirmation (HPLC/LCMS), and blockchain-secured data analytics. Built on blockchain distributed ledger technology, includes Verify LIMS and PADReader mobile app, and covers approximately 300 commonly prescribed medicines including nearly half of WHO Essential Medicines. Sold via subscription to healthcare organizations, pharmaceutical supply chain providers, and research institutions.
- ARTiFACTS File Platform for curation of ancillary scientific research material (grey literature), enabling researchers to upload data, establish proofs-of-existence, manage, track, link, display, analyze and create reports of artifacts using blockchain distributed ledgers. For the scientific research community.
Quantifiable outcome
- 10-30% of medicines in global supply chains can be identified as substandard or falsified using Verify's chemical analysis
- +3 more outcomes
Companies that use ARTiFACTS
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
ARTiFACTS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability6 records
Feature6 records
ARTiFACTS partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- BoKoMo FoundationcoreU.S.-based 501(c)(3) non-profit organization founded by Dr. Marya Lieberman to further pioneering research and advance low-cost chemical screening technologies. In June 2026, Artifactsofresearch, Inc. donated 100% of its shares to BoKoMo. Artifactsofresearch, Inc. now operates as a subsidiary, licensing technology to the foundation free of charge to support its charitable mission. BoKoMo emphasizes accessibility through affordable sliding-scale pricing and global data sharing.
- Lieberman Lab at University of Notre DamecorePrimary academic research partner leading the Distributed Pharmaceutical Analysis Lab (DPAL) initiative. The partnership leverages ARTiFACTS Verify platform to manage and conduct post-market surveillance of pharmaceutical quality across LMICs. The Lieberman Lab oversees a global network of academic laboratories and collaborators working to detect and report substandard and falsified drugs.
- DPAL (Distributed Pharmaceutical Analytical Laboratories) NetworkcoreNetwork of 29 academic institutions across the US and globally performing pharmaceutical analysis using PAD technology. DPAL collects samples from pharmacies in developing countries (Kenya, Uganda, Tanzania, India, Nepal, Malawi) and conducts chemical characterization of suspect medications. The network is expanding to include more countries and products.
- Chemists Without BordersminorCollaborative partner providing analytical resources and support for pharmaceutical analysis in developing regions. Contributes to the overall mission of expanding testing capacity for SF drug detection in LMICs.
- Certified Commercial LaboratoriescoreIndependent certified commercial laboratories contracted to perform HPLC, LCMS, and other sophisticated analyses to confirm APIs in suspect samples. Services are secured based on customer requirements and included in subscription offering.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
ARTiFACTS competitors and assessment
Company assessmentDirect peers
- Sproxil: Sproxil provides mobile-based authentication and verification of pharmaceutical products in emerging markets to combat counterfeiting. It is a direct competitor in the same SF drug detection category, particularly across African and Asian supply chains.
- mPedigree: mPedigree offers mobile authentication and supply-chain visibility for pharmaceutical products in Africa and other emerging markets, addressing the same falsified-medicine problem with similar field-to-cloud verification flows.
- PharmaSecure: PharmaSecure provides anti-counterfeiting and supply-chain traceability solutions for the pharmaceutical industry, including serialization and verification. It overlaps directly with ARTiFACTS on the SF drug detection value proposition.
- RxAll: RxAll operates a proprietary drug authentication scanner plus marketplace for verifying medicine quality, particularly in African markets. The hardware-plus-AI approach for pharmacy-level quality screening is a close analog to ARTiFACTS' PAD + neural network stack.
Others
- LabWare: LabWare is a leading provider of Laboratory Information Management Systems (LIMS) used across pharmaceutical, environmental, and clinical laboratories. It is an adjacent enabling player whose LIMS capabilities overlap with ARTiFACTS' Verify LIMS substrate.
Broad incumbents
- TraceLink: TraceLink is a leading pharmaceutical serialization and track-and-trace network serving DSCSA and global compliance mandates. It addresses supply-chain integrity from a digital pedigree angle that overlaps with but is broader than ARTiFACTS' chemical verification focus.
- Optel Group: Optel is a global provider of traceability systems for pharmaceuticals, including serialization, aggregation, and supply-chain visibility. Its pharma supply-chain focus and DSCSA compliance tools make it a comparable broader incumbent.
- Systech (Dover): Systech provides serialization, track-and-trace, and authentication solutions for the pharmaceutical and life sciences industries. It is a broader incumbent in supply-chain integrity with overlapping pharma customer relationships.
- Truven Health Analytics (IBM Watson Health): Truven Health Analytics is a healthcare data analytics and consulting firm (now part of IBM Watson Health) whose former CEO sits on ARTiFACTS' board. Comparable in the US healthcare analytics and outcomes space and signals the type of incumbent the platform could partner with or compete against.
- SAP Advanced Track and Trace for Pharmaceuticals: SAP ATTP is an enterprise-scale serialization and track-and-trace platform used by large pharma manufacturers to meet global supply-chain compliance. It competes for the same pharma compliance wallet with a digital-only approach versus ARTiFACTS' chemical verification.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ARTiFACTS social profiles
Digital presenceARTiFACTS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARTiFACTS leadership team
Management profileNumber of profiles
Profiles3 records
ARTiFACTS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARTiFACTS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARTiFACTS
What does ARTiFACTS do?
ARTiFACTS operates a cloud-based SaaS platform called Artifacts VERIFY that combines paper analytical device (PAD) field testing of medicines, AI-powered mobile diagnostics, certified laboratory confirmation (HPLC/LCMS), and blockchain-secured data analytics to detect and report substandard and falsified pharmaceuticals across the supply chain. The platform provides a Laboratory Information Management System (LIMS) for tracking samples, protocols, results, users, and procedures, and delivers real-time reporting by API, location, lot number, and manufacturer.
Is ARTiFACTS a public or private company?
ARTiFACTS is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was ARTiFACTS founded?
ARTiFACTS was founded in 2018. It employs 1 to 10 people.
Where is ARTiFACTS based?
ARTiFACTS is headquartered in San Diego, United States, in the North America region.
How does ARTiFACTS make money?
Two revenue lines are on record. Software Subscription (VERIFY Platform) is the primary driver. The others are laboratory Services.
Who are ARTiFACTS's main competitors?
Direct peers on record are Sproxil, mPedigree, PharmaSecure and RxAll. LabWare is listed as an others. Broad incumbents are TraceLink, Optel Group, Systech (Dover), Truven Health Analytics (IBM Watson Health) and SAP Advanced Track and Trace for Pharmaceuticals.
Does ARTiFACTS have an API?
No public API is recorded for ARTiFACTS.
What industry is ARTiFACTS in?
ARTiFACTS's product category is Pharmaceutical Quality Monitoring Software. Its primary akta.pro industry code is HLAGADAM, Forensic & Anti-Counterfeit Testing (Product Integrity), with a secondary code of IMAGAFAC, Test & Measurement Equipment (Oscilloscopes, DAQ, signal analyzers, calibration benches). Its NAICS code is 54138 and its SIC code is 3826.